Home LiteratureArticle Details
PMID: 8756654 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.

Molecular and cellular biology ·Vol. 16 ·No. 9 ·1996-09-00 ·Pages 4952-60

Ludwig RL, Bates S, Vousden KH

Abstract

The p53 tumor suppressor protein is a sequence-specific transcriptional activator, a function which contributes to cell cycle arrest and apoptosis induced by p53 in appropriate cell types. Analysis of a series of p53 point mutants has revealed the potential for selective loss of the ability to transactivate some, but not all, cellular p53-responsive promoters. p53 175P and p53 181L are tumor-derived p53 point mutants which were previously characterized as transcriptionally active. Both mutants retained the ability to activate expression of the cyclin-dependent kinase inhibitor p2lcip1/waf1, and this activity correlated with the ability to induce a G1 cell cycle arrest. However, an extension of this survey to include other p53 targets showed that p53 175P was defective in the activation of p53-responsive sequences derived from the bax promoter and the insulin-like growth factor-binding protein 3 gene (IGF-BP3) promoter, while p53 181L showed loss of the ability to activate a promoter containing IGF-BP3 box B sequences. Failure to activate transcription was also reflected in the reduced ability of the mutants to bind the p53-responsive DNA sequences present in these promoters. These specific defects in transcriptional activation correlated with the impaired apoptotic function displayed by these mutants, and the results suggest that activation of cell cycle arrest genes by p53 can be separated from activation of genes with a role in mediating the p53 apoptotic response. The cellular response to p53 activation may therefore depend, at least in part, on which group of p53-responsive genes become transcriptionally activated.

MeSH Terms
Apoptosis/physiology Cell Cycle/genetics Cyclin-Dependent Kinase Inhibitor p21 Cyclins/metabolism DNA/metabolism Enzyme Activation Gene Expression Regulation Genes, p53 Humans Neoplasm Proteins/metabolism Neoplasms/genetics,pathology Point Mutation Promoter Regions, Genetic Proto-Oncogene Proteins/metabolism Proto-Oncogene Proteins c-bcl-2 Transfection Tumor Cells, Cultured Tumor Suppressor Protein p53/genetics,physiology bcl-2-Associated X Protein
Chemicals
BAX protein, human CDKN1A protein, human Cyclin-Dependent Kinase Inhibitor p21 Cyclins Neoplasm Proteins Proto-Oncogene Proteins Proto-Oncogene Proteins c-bcl-2 Tumor Suppressor Protein p53 bcl-2-Associated X Protein DNA
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Ludwig R L
ABL Basic Research Program, National Cancer Institute-Frederick Cancer Research and Developmental Center, Maryland 21702-1201, USA.
Bates S
Vousden K H
References (54)
54 references, click to expand
  1. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor.
    Mol Cell Biol. 1995 Dec;15(12):6953-60 PMID: 8524262
  2. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective.
    EMBO J. 1995 Oct 16;14(20):4994-5005 PMID: 7588628
  3. Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis.
    Cell Growth Differ. 1995 Oct;6(10):1207-12 PMID: 8845297
  4. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6.
    Virology. 1996 Mar 1;217(1):285-92 PMID: 8599213
  5. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
    EMBO J. 1996 Feb 15;15(4):827-38 PMID: 8631304
  6. Cell type-specific inhibition of p53-mediated apoptosis by mdm2.
    EMBO J. 1996 Apr 1;15(7):1596-606 PMID: 8612583
  7. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.
    Mol Cell Biol. 1996 Sep;16(9):4961-71 PMID: 8756655
  8. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues.
    Am J Pathol. 1996 Mar;148(3):825-35 PMID: 8774137
  9. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.
    Eur J Biochem. 1986 Sep 15;159(3):529-34 PMID: 2428616
  10. Structural aspects of the p53 protein in relation to gene evolution.
    Oncogene. 1990 Jul;5(7):945-52 PMID: 2142762
  11. Suppression of human colorectal carcinoma cell growth by wild-type p53.
    Science. 1990 Aug 24;249(4971):912-5 PMID: 2144057
  12. p53 functions as a cell cycle control protein in osteosarcomas.
    Mol Cell Biol. 1990 Nov;10(11):5772-81 PMID: 2233717
  13. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
    Science. 1990 Nov 30;250(4985):1233-8 PMID: 1978757
  14. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.
    Nature. 1990 Dec 20-27;348(6303):747-9 PMID: 2259385
  15. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.
    Nature. 1991 Jul 25;352(6333):345-7 PMID: 1852210
  16. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Nature. 1992 Mar 19;356(6366):215-21 PMID: 1552940
  17. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.
    J Immunol Methods. 1992 Jul 6;151(1-2):237-44 PMID: 1378473
  18. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.
    EMBO J. 1992 Nov;11(11):3935-40 PMID: 1327751
  19. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents.
    J Exp Med. 1992 Oct 1;176(4):1043-51 PMID: 1402650
  20. Regulation of the specific DNA binding function of p53.
    Cell. 1992 Nov 27;71(5):875-86 PMID: 1423635
  21. Definition of a consensus binding site for p53.
    Nat Genet. 1992 Apr;1(1):45-9 PMID: 1301998
  22. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription.
    EMBO J. 1993 Jul;12(7):2705-13 PMID: 8334989
  23. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
    Oncogene. 1993 Aug;8(8):2159-66 PMID: 8336941
  24. WAF1, a potential mediator of p53 tumor suppression.
    Cell. 1993 Nov 19;75(4):817-25 PMID: 8242752
  25. p21 is a universal inhibitor of cyclin kinases.
    Nature. 1993 Dec 16;366(6456):701-4 PMID: 8259214
  26. Modulation of transcriptional regulatory properties of p53 by HPV E6.
    Oncogene. 1994 Apr;9(4):1225-30 PMID: 8134125
  27. Sequence-specific transcriptional activation is essential for growth suppression by p53.
    Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1998-2002 PMID: 8134338
  28. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.
    Cell. 1994 Mar 25;76(6):1013-23 PMID: 8137420
  29. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal.
    EMBO J. 1994 Mar 15;13(6):1368-74 PMID: 8137820
  30. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
    Oncogene. 1994 Jun;9(6):1799-805 PMID: 8183579
  31. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7.
    Proc Natl Acad Sci U S A. 1994 May 10;91(10):4382-6 PMID: 8183918
  32. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein.
    Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5320-4 PMID: 8202487
  33. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes.
    Nature. 1994 Jul 21;370(6486):220-3 PMID: 8028670
  34. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation.
    Oncogene. 1994 Aug;9(8):2177-81 PMID: 8036003
  35. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines.
    EMBO J. 1994 Jul 15;13(14):3286-95 PMID: 8045259
  36. Tumor spectrum analysis in p53-mutant mice.
    Curr Biol. 1994 Jan 1;4(1):1-7 PMID: 7922305
  37. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
    Genes Dev. 1994 May 15;8(10):1235-46 PMID: 7926727
  38. Database of p53 gene somatic mutations in human tumors and cell lines.
    Nucleic Acids Res. 1994 Sep;22(17):3551-5 PMID: 7937055
  39. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.
    Genes Dev. 1994 Dec 1;8(23):2817-30 PMID: 7995520
  40. Transcriptional activation by p53 correlates with suppression of growth but not transformation.
    Cell. 1994 Dec 2;79(5):817-27 PMID: 8001119
  41. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.
    Cell. 1995 Jan 27;80(2):293-9 PMID: 7834749
  42. Growth factor modulation of p53-mediated growth arrest versus apoptosis.
    Genes Dev. 1995 Mar 1;9(5):600-11 PMID: 7698649
  43. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB.
    Oncogene. 1995 Apr 20;10(8):1563-71 PMID: 7731711
  44. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.
    Mol Cell Biol. 1995 Jun;15(6):3032-40 PMID: 7539102
  45. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases.
    Nature. 1995 Jul 6;376(6535):88-91 PMID: 7596441
  46. Discrimination of DNA binding sites by mutant p53 proteins.
    Mol Cell Biol. 1995 Sep;15(9):5196-202 PMID: 7651437
  47. Induction of apoptosis in HeLa cells by trans-activation-deficient p53.
    Genes Dev. 1995 Sep 1;9(17):2170-83 PMID: 7657168
  48. Essential role for p53-mediated transcription in E1A-induced apoptosis.
    Genes Dev. 1995 Sep 1;9(17):2184-92 PMID: 7657169
  49. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.
    Cell. 1995 Aug 25;82(4):675-84 PMID: 7664346
  50. Bax-deficient mice with lymphoid hyperplasia and male germ cell death.
    Science. 1995 Oct 6;270(5233):96-9 PMID: 7569956
  51. Radiation-induced cell cycle arrest compromised by p21 deficiency.
    Nature. 1995 Oct 12;377(6549):552-7 PMID: 7566157
  52. Induction of the growth inhibitor IGF-binding protein 3 by p53.
    Nature. 1995 Oct 19;377(6550):646-9 PMID: 7566179
  53. p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
    Cancer Res. 1995 Nov 15;55(22):5187-90 PMID: 7585571
  54. Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis.
    Oncogene. 1995 Dec 7;11(11):2311-6 PMID: 8570182
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
1996-09-00
Pages
4952-60
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC231497
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com